Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer.
Safety profiles of first-line therapies for metastatic non-squamous non-small-cell lung cancer. Expert Opin Drug Saf. 2016 Mar 23; Authors: Losanno T, Gridelli C Abstract Introduction - Lung cancer still represents the leading cause of death for cancer. About the 70% of diagnosis are in advanced-stage. Non-small-cell lung cancer (NSCLC) represents the 85% of all diagnosed lung cancers and non-squamous histology represents the 40% of all NSCLC. First-line therapies increase survival, control symptoms and improve quality of life, compared with best supportive care. It is crucial to choose a treatment with a low impact on patient's life considering the related toxicities. Areas covered - Adverse events (AEs) of first-line therapies for non-squamous NSCLC are here reviewed and discussed, from evidences in clinical trials conducting to drugs approval. Expert opinion - For advanced disease, palliation and preserving patients QoL are still the primary goal of treatment. Therefore, differing toxicity profiles are often a deciding factor in first-line and also maintenance setting for non-squamous NSCLC. Special attention is necessary to renal function and drugs' nephrotoxicity. Moreover, it is to consider the specific AEs of drugs classes: hypertension, bleeding, and proteinuria, for anti-VEGF therapy; skin toxicity, diarrhea, interstitial lung disease for TKIs; vision disorders, and hepatotoxicity for ALK-inhibitor. It is important to select patients for a treatm...
SUPPLEMENTS could be used to improve the health of your heart, as well as to protect against high blood pressure symptoms and signs. Add these cheap garlic capsules to your diet to lower your risk of heart problems, including heart attacks and heart disease.
Those suffering from cancer, heart conditions, strokes, diabetes and lung disease are among the worst affected by delays to their diagnosis and care, a survey of senior doctors reveals.
HIGH blood pressure is a largely symptomless silent killer. If a person ignores their blood pressure because they think a certain symptom will alert them to the problem, they are taking a dangerous chance with their life. There are two waring signs which lay in a person's face.
The objective of this study was to report the incidence of alopecia arising in patients treated with vismodegib, assessing its characteristics, grade of severity, and time of onset.Skin Appendage Disord
CONCLUSIONS: Surprisingly, the DCR registered fewer patients in 2013-2014 than the DLCR, even though they employ the same primary data source. The agreement between the DCR and the DLCR was 87%; this may be increased to 95% if patients who seemed to meet the inclusion criteria of the other register were also included. The discrepancies found were mainly due to different definitions of dates of diagnosis, registrations probably missed by the algorithms and possible registration errors. Discrepancies resulted in a significant difference in MRR, but not in 1y-RS. FUNDING: none. TRIAL REGISTRATION: not relevant. PM...
CONCLUSIONS: Most women did not experience any improvement in their symptoms over time, and no association was found between lack of symptom improvement and believing that the HPV vaccine was causing the symptoms. FUNDING: funded by the Danish Cancer Society. TRIAL REGISTRATION: not relevant. PMID: 32741432 [PubMed - in process]
Conclusions: Changing national guidelines with discard of contraindications for anticoagulation and the introduction of DOACs led to a broader recommendation of oral anticoagulation. However, both, new guidelines and DOACs, were not found to be associated with an increasing percentage of patients discharged from our hospital already on recommended anticoagulant prevention. This might be explained by the decreasing length of hospital stay during the study period and a missing evidence of early bleeding risk of DOACs in patients with acute brain infarction. Evidence-based data to close this therapeutic gap are needed.Cerebrovasc Dis
Conclusions: In our large cohort of CAS patients, coexistent UIAs are not uncommon. Stenting of a carotid artery in the presence of coexistent UIAs could be conducted safely. Together with 3-month dual antiplatelet therapy, CAS did not increase the rupture risk of the coexistent UIAs within 3 months.Cerebrovasc Dis
Date: Friday, 09 25, 2020; Speaker: Dr. Dauod Meerzaman; Building: Building 10 (Clinical Center); This class is presented as a webinar only; Videocast Event
Date: Wednesday, 05 12, 2021; Speaker: Christine Ambrosone, Ph.D., University of Buffalo; 6100 Executive Boulevard; 3rd Floor Conference Room